---
$id: https://graph.org.ai/products/commodity/51111617
$type: Product
source: UNSPSC
code: "51111617"
title: "Gemcitabine"
class: "51111600"
classTitle: "Antimetabolites"
family: "51110000"
familyTitle: "Antineoplastic agents"
segment: "51000000"
segmentTitle: "Pharmaceutical Products incl. Contraceptives and Vaccines"


---

# Gemcitabine

**UNSPSC Code**: 51111617
**Class**: [Antimetabolites](Antimetabolites.mdx)
**Family**: [Antineoplastic agents](../Antineoplastic agents.mdx)
**Segment**: [Pharmaceutical Products incl. Contraceptives and Vaccines](../../Pharmaceutical Products incl. Contraceptives and Vaccines.mdx)

This classification denotes a ribonucleotide reductase inhibitor and pyrimidine antagonist with the molecular formula C9H11F2N3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B76N6SBZ8R, chemically known as 2-deoxy-.beta.-d-2,2-difluorocytidine but generally known as gemcitabine, which bears US NIH Compound Identifier 60750. European Medicines Agency schedules Gemcitabine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07892MIG. The term GEMCITABINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, No. 3 1990, List 30). World Health Organization schedules gemcitabine in its Anatomical Therapeutic Chemical (ATC) Classification. GEMCITABINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule gemcitabine under HS 29349990 and SITC 51579. As of Q4 2014, GEMCITABINE remains the US FDA Preferred Term for this commodity. Gemcitabine bears US NLM identifiers UMLS ID C0045093 and NCI Concept Code C66876. SMILES: FC1(F)C(O)C(OC1N1CCC(NC1=O)N)CO.

